Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy

• Hoofdauteurs: Miaomiao Gong (Auteur), Qi Zhang (Auteur), Qi Zhao (Auteur), Jiani Zheng (Auteur), Yue Li (Auteur), Siling Wang (Auteur), Yue Yuan (Auteur)
• Formaat: Boek
• Gepubliceerd in: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.
• Notes: 1071-7544; 1521-0464; 10.1080/10717544.2019.1618420
• Keywords: synthetic high-density lipoprotein; mimetic peptide; docetaxel; breast cancer; anticancer; Therapeutics. Pharmacology; RM1-950
• Source: Drug Delivery, Vol 26, Iss 1, Pp 708-716 (2019)

In this study, a synthetic high-density lipoprotein (sHDL), peptide-based nanocarrier loaded with docetaxel (DTX) was constructed, against breast cancer. The thermodynamic and molecular dynamic analyses were conducted to examine the stability of nanoparticles synthesized from mimetic peptide 5 A and various types of phospholipids. Furthermore, the cellular uptake and in vivo fluorescence imaging analysis experiments, with scavenger receptor B-I (SR-BI) were carried out to examine the tumor-targeting ability of sHDL. The nanoparticles were investigated for their pharmacodynamic and cytotoxic effects to show their effectivity as anti-tumor agents. The results showed that the synthesized sHDL nanoparticles exhibited a high payload of DTX, sustained drug release properties, and excellent biocompatibility. Moreover, DTX-sHDL nanoparticles enhanced the uptake of DTX, increased the cytotoxicity against MCF-7 cells, and reduced the off-target side-effects to normal cells. Finally, experiments in 4T1 cell line-bearing mice indicate that inhibition of tumor growth by DTX-sHDL nanoparticles was superior to that of free DTX group. Thus, the sHDL nanoparticles are a promising drug delivery vehicle for improving the efficacy of anti-cancer drugs.